Atara Biotherapeutics(ATRA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress Tab-cel ® U.S. BLA On-Track With PDUFA Target Action Date of January 15, 2025 First Patient Dosed for ATA3219 Non-Hodgkin's Lymphoma Study; Initial Clinical Data Expected Q1 2025 ATA3219 Lupus Nephritis and Extrarenal Systemic Lupus Erythematosus Study Initiation Expected by End of Year; Initial Clinical Data Expected Mid-2025 Cash Runway Into 2027 Enables Key Pipeline Readouts THOUSAND OAKS, Calif.—No ...